NEW YORK (GenomeWeb) – OncoCyte announced today it has reached definitive agreements with certain investors for the purchase of units to raise approximately $3.6 million in gross proceeds.

The investors include members of OncoCyte's management and its board, as well as new institutional investors, the company said. Net proceeds from the offering will be used for working capital, including further development of the company's confirmatory lung cancer diagnostic test called DetermaVu, and other general corporate purposes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.